Evidence Hub

Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women

Scott G, Yiu SC, Wasilewski D, Song J, Smith RE

American journal of ophthalmology, 2005

11 participants

Abstract

PURPOSE: To determine whether systemic replacement with combined esterified estrogen (EE) and methyltestosterone (MT) (EE + MT) would reduce symptoms and promote clinical improvement in postmenopausal women with dry eye syndrome (DES).

DESIGN: Retrospective, noncomparative, interventional case series.

METHODS: Investigators reviewed the charts of 11 postmenopausal women treated within the last 3 years with EE + MT.

RESULTS: The mean patient age was 65.2 years (standard deviation [SD] 11.4, range 48-84 years). The mean treatment duration was 12.2 months (SD 6.2 months, range 4-24 months). Ten (91%) of 11 patients reported improvement in dry eye symptoms while receiving treatment. For these 10, relief occurred after an average of 4.1 months of treatment (SD 3.2, range, 1-9 months).

CONCLUSIONS: Treatment with EE + MT may be efficacious for DES of various etiologies. A randomized placebo-controlled trial is planned to further evaluate these encouraging findings.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 11 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free